These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35717457)

  • 1. Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study.
    Ruffatti A; Cerutti A; Tonello M; Favaro M; Del Ross T; Calligaro A; Grava C; Zen M; Hoxha A; Di Salvo G
    J Perinatol; 2022 Sep; 42(9):1161-1168. PubMed ID: 35717457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination therapy to treat second-degree anti-Ro/La-related congenital heart block: a strategy to avoid stable third-degree heart block?
    Ruffatti A; Milanesi O; Chiandetti L; Cerutti A; Gervasi MT; De Silvestro G; Pengo V; Punzi L
    Lupus; 2012 May; 21(6):666-71. PubMed ID: 22187163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmapheresis, intravenous immunoglobulins and bethametasone - a combined protocol to treat autoimmune congenital heart block: a prospective cohort study.
    Ruffatti A; Cerutti A; Favaro M; Del Ross T; Calligaro A; Hoxha A; Marson P; Leoni L; Milanesi O
    Clin Exp Rheumatol; 2016; 34(4):706-13. PubMed ID: 27385463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antenatal and postnatal combined therapy for autoantibody-related congenital atrioventricular block.
    Di Mauro A; Caroli Casavola V; Favia Guarnieri G; Calderoni G; Cicinelli E; Laforgia N
    BMC Pregnancy Childbirth; 2013 Nov; 13():220. PubMed ID: 24286473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature.
    Ruffatti A; Marson P; Svaluto-Moreolo G; Marozio L; Tibaldi M; Favaro M; Calligaro A; Grava C; Hoxha A; Pengo V; Punzi L
    Autoimmun Rev; 2013 May; 12(7):768-73. PubMed ID: 23340276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block.
    Routsias JG; Kyriakidis NC; Friedman DM; Llanos C; Clancy R; Moutsopoulos HM; Buyon J; Tzioufas AG
    Arthritis Rheum; 2011 Sep; 63(9):2783-9. PubMed ID: 21618202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment in utero of autoimmune-associated congenital heart block.
    Saxena A; Izmirly PM; Mendez B; Buyon JP; Friedman DM
    Cardiol Rev; 2014; 22(6):263-7. PubMed ID: 25050975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies.
    Buyon JP; Winchester RJ; Slade SG; Arnett F; Copel J; Friedman D; Lockshin MD
    Arthritis Rheum; 1993 Sep; 36(9):1263-73. PubMed ID: 8216420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two case reports of neonatal autoantibody-associated congenital heart block.
    Li X; Huang X; Lu H
    Medicine (Baltimore); 2018 Nov; 97(45):e13185. PubMed ID: 30407356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin.
    David AL; Ataullah I; Yates R; Sullivan I; Charles P; Williams D
    Obstet Gynecol; 2010 Aug; 116 Suppl 2():543-547. PubMed ID: 20664449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus.
    Saleeb S; Copel J; Friedman D; Buyon JP
    Arthritis Rheum; 1999 Nov; 42(11):2335-45. PubMed ID: 10555029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial.
    Friedman DM; Llanos C; Izmirly PM; Brock B; Byron J; Copel J; Cummiskey K; Dooley MA; Foley J; Graves C; Hendershott C; Kates R; Komissarova EV; Miller M; Paré E; Phoon CK; Prosen T; Reisner D; Ruderman E; Samuels P; Yu JK; Kim MY; Buyon JP
    Arthritis Rheum; 2010 Apr; 62(4):1138-46. PubMed ID: 20391423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective.
    Friedman DM; Rupel A; Glickstein J; Buyon JP
    Indian J Pediatr; 2002 Jun; 69(6):517-22. PubMed ID: 12139139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibody-associated congenital heart block: outcome in mothers and children.
    Waltuck J; Buyon JP
    Ann Intern Med; 1994 Apr; 120(7):544-51. PubMed ID: 8116991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block.
    Ruffatti A; Favaro M; Brucato A; Ramoni V; Facchinetti M; Tonello M; Del Ross T; Calligaro A; Hoxha A; Grava C; De Silvestro G
    Transfus Apher Sci; 2015 Dec; 53(3):269-78. PubMed ID: 26626966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern.
    Ambrosi A; Salomonsson S; Eliasson H; Zeffer E; Skog A; Dzikaite V; Bergman G; Fernlund E; Tingström J; Theander E; Rydberg A; Skogh T; Öhman A; Lundström U; Mellander M; Winqvist O; Fored M; Ekbom A; Alfredsson L; Källberg H; Olsson T; Gadler F; Jonzon A; Kockum I; Sonesson SE; Wahren-Herlenius M
    Ann Rheum Dis; 2012 Mar; 71(3):334-40. PubMed ID: 21953338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of congenital heart block in children of SSA-positive mothers.
    Brucato A
    Rheumatology (Oxford); 2008 Jun; 47 Suppl 3():iii35-7. PubMed ID: 18504284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma exchange effectively removes 52- and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with congenital heart block.
    Tonello M; Ruffatti A; Marson P; Tison T; Marozio L; Hoxha A; De Silvestro G; Punzi L
    Transfusion; 2015 Jul; 55(7):1782-6. PubMed ID: 25825254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block.
    Mevorach D; Elchalal U; Rein AJ
    Curr Opin Rheumatol; 2009 Sep; 21(5):478-82. PubMed ID: 19584727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.
    Izmirly P; Kim M; Friedman DM; Costedoat-Chalumeau N; Clancy R; Copel JA; Phoon CKL; Cuneo BF; Cohen RE; Robins K; Masson M; Wainwright BJ; Zahr N; Saxena A; Buyon JP
    J Am Coll Cardiol; 2020 Jul; 76(3):292-302. PubMed ID: 32674792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.